



Atty. Dkt. No. BERLX-88

#10/a  
2-25-03

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: CROZE, EDWARD M.

Title: NOVEL INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Appl. No. 09/881,050

Filing Date: June 15, 2001

Examiner:

Art Unit:

**AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§1.821-825**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Applications Containing Sequence Disclosures mailed June 26, 2002, please amend the application as follows:

**In the Specification:**

Please amend the specification as shown:

Please delete the paragraph on page 1, lines 10-11, and replace it with the following paragraph:

a1 Fig. 1 shows the nucleotide sequence (SEQ ID NO: 15) of human interferon-beta-2, including 5' and 3' sequences.

Please delete the paragraph on page 1, lines 12-15, and replace it with the following paragraph:

a2 Fig. 2 shows the amino acid sequence (SEQ ID NO: 16) of human interferon-beta-2. The translation of the open reading frame for IFN-β2 is shown. The signal sequence is shown italicized and the